ITEM 8.01  OTHER EVENTS
On January 18, 2022, Revance Therapeutics, Inc. (the "Company") announced that
it received the official Type A meeting minutes from the United States (U.S.)
Food and Drug Administration (the "FDA") regarding the Complete Response Letter
("CRL") previously issued with respect to the Company's Biologics License
Application (the "BLA") for DaxibotulinumtoxinA for Injection for the treatment
of moderate to severe glabellar (frown) lines. The Type A meeting was held on
December 15, 2021.
Based on the meeting minutes, received by the Company on January 14, 2022, a
complete response to address the outstanding observations related to the working
cell bank ("WCB") and the drug substance manufacturing process will require the
Company to qualify its new WCB by producing three consecutive drug substance
lots and one drug product lot. The qualification of the new WCB has been
underway, and the Company plans to submit the new WCB qualification package as
part of its BLA resubmission as soon as possible. A reinspection of the
Company's manufacturing facility will be required once the resubmission is
accepted by the FDA.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses